Liver impairment study tests drug processing in 33 volunteers
NCT ID NCT06813781
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how a single dose of the drug AZD5004 moves through the body in people with mild, moderate, or severe liver impairment compared to healthy volunteers. The goal was to measure drug levels and check safety. 33 adults aged 18-80 took part. The results will help guide future dosing for patients with liver issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5004 (also known as ECC5004)
What this could lead to
If successful, this study could help doctors understand how to safely dose AZD5004 in patients with liver problems.
What could go wrong
This is a very early Phase 1 study with only 33 participants. It is designed to measure drug levels, not to treat any disease, so it may not lead to a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Lake Forest, California, 92630, United States
-
Research Site
Rialto, California, 92377, United States
-
Research Site
Miami Lakes, Florida, 33014, United States
-
Research Site
Orlando, Florida, 32809, United States
-
Research Site
San Antonio, Texas, 78215, United States